0      0


JL1104EH - JL1104EH: Efficacy and safety of glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥2 prior therapies: pivotal results from a Phase II expansion study


‐ Nov 2, 2023 2:00pm


Presenter(s):

You must be logged in and own this session in order to post comments.